The present invention relates to a device and method for separating serum or plasma from whole blood.
Many in vitro diagnostic testing systems and protocols require the use of blood specimens that are free of blood cells in order to perform a diagnostic test. These diagnostic tests either use serum or plasma which is separated from whole blood using techniques such as centrifugation or filtration.
Serum can be separated from whole blood by first allowing the blood to clot and then centrifuging the specimen to move all the blood cells to the bottom of the specimen tube. Plasma can be separated from whole blood by first mixing the whole blood with an anticoagulant such as lithium heparin or potassium EDTA and then centrifuging the specimen to move all the blood cells to the bottom of the specimen tube.
When using centrifugation to separate serum or plasma from whole blood, it is common to use a specimen tube that contains a thixotropic gel which has a greater specific gravity than serum or plasma, but lower specific gravity than blood cells. During centrifugation, this gel migrates above the blood cells while staying below the serum or plasma. The function of the gel is to provide a barrier between the serum or plasma and the blood cells so that the serum or plasma do not remix with the blood cells after centrifugation.
One difficulty of using serum or plasma from centrifuged specimen tubes is that it is difficult to extract serum or plasma from the specimen tube without leaving a large dead volume. The term “dead volume” refers to the amount of unusable sample left in the specimen tube after the maximum amount of sample has been extracted. When using an automated or manual pipette to extract sample from a centrifuged specimen tube, there is a risk that the pipette will make contact with either the blood cells or the gel separator. If this occurs, the sample may be disturbed remixing the blood cells and serum or plasma, the pipette may get clogged, or the pipette may not extract pure serum or plasma. To avoid these risks, the pipette must be kept a safe depth above the blood cells or gel separator to ensure it does not make contact with the blood cells or the gel separator. For an automated pipette, this means that the pipette depth is controlled such that the pipette tip keeps a safe distance from the blood cells or the gel separator. For a manual pipette, this means that the user exercises caution to keep the pipette a safe distance from the blood cells or the gel separator. The serum or plasma which is above the blood cells or the gel separator yet below the pipette tip is unusable as it won't be extracted in the pipette.
Leaving a large dead volume may not be problematic when the amount of serum or plasma available is significantly greater than the amount required by the diagnostic tests. However, as the amount of serum or plasma required by the diagnostic tests approaches the amount of serum or plasma available, dead volume becomes a greater concern. This is particularly important when using small volume sample collection technologies or in pediatric samples where the amount of blood able to be drawn is more limited.
In cases where it is not possible to collect larger amounts of a blood specimen, one common technique to reduce the dead volume left when pipetting from a centrifuged specimen container is to pour the serum or plasma out of the centrifuged specimen tube, into a secondary specimen tube. Because the secondary specimen tube does not contain blood cells or gel separator, a pipette can safely dive to the bottom of the specimen tube and the serum or plasma can be extracted with a low dead volume. While this technique results in a low dead volume, there are several significant disadvantages. This technique consumes an additional specimen container, which results in added material costs. The step of pouring serum or plasma increases labor costs and introduces risk of human error. There is also a risk of specimen mix-up if the new specimen tube is not properly labeled.
In order to, inter alia, make a blood draw less invasive and decrease the costs of the running diagnostic tests, many companies are currently developing specimen collection and processing techniques based on smaller sample volumes than are collected by most labs today. In order to effectively run diagnostic tests using serum or plasma collected in small volumes, approaches are needed to minimize the loss of serum or plasma due to dead volume. This invention enables diagnostic laboratories to effectively run diagnostic tests using smaller blood specimens or run more tests with the same volume of blood specimen.
Provided herein is a device for separating serum or plasma from blood cells in a whole blood specimen. The present invention uses a cap with a reservoir, such that blood cells are packed into the cap when a specimen tube is centrifuged with the capped end away from the axis of centrifugation. When the cap is removed, the blood cells are also removed, so that the serum or plasma is left in the specimen tube where it can be readily extracted by a pipette which is able to reach all the way to the bottom of the specimen tube minimizing the dead volume.
Various terms relating to aspects of the description are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definitions provided herein.
As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise.
The term “about” as used herein when referring to a measurable value such as an amount and the like, is meant to encompass variations of up to ±30% from the specified value, as such variations are appropriate to perform the disclosed methods. Unless otherwise indicated, all numbers expressing quantities of properties such as volume and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention.
The specimen tube 1 and cap 10 have a mechanism by which the open end 4 of the specimen tube 1 may be secured with the open end 12 of the cap 10 to form a specimen container, such that the blood specimen is contained within the specimen tube 1 and the cap 10. The mechanism for securing the specimen tube 1 and the cap 10 can be any mechanism desired as long as the specimen tube and cap are secured to create a leak free fitting. It is important that the contents of the specimen container do not leak when the specimen container is oriented in any direction. Such mechanisms for securing the specimen tube to the cap can include an engineered fit or interference fit. A preferred engineered fit is a threaded connection 7 where the specimen tube and the cap both have screw threads that work to connect the specimen tube and the cap together as shown in the figures. Any other engineered fit can be used that creates a leak free locking mechanism. Alternatively, an interference fit can be used such that the specimen tube and the cap are secured by friction after the open end of the specimen tube and open end of the cap are pushed together. For example, the cap can be a plug that is secured onto the open end of the specimen tube. Optionally, the joint between the specimen tube and the cap can be sealed using a gasket. The mechanism to secure the specimen tube and cap together is not limited to any particular mechanism and shall include any mechanism whereby the specimen tube and cap can be secured together to create a leak free specimen container.
In
For purposes of this invention, a separator is a device that is put into a specimen tube (or alternatively, into a cap) in order to ensure that after the specimen tube is centrifuged, there is a physical layer separating the serum or plasma from the blood cells and other solids. The separator is chosen such that it has a higher specific gravity than serum and/or plasma and lower specific gravity than blood cells and other solids in the blood to be removed. During centrifugation, the serum or plasma is separated from blood cells and any other solids in the blood by migrating closer to the axis of centrifugation because it has lower specific gravity. The blood cells (and other solids) migrate further away from the axis of centrifugation because they have higher specific gravity. The separator migrates to a level between the serum or plasma and the blood cells (and other solids), because it has intermediate specific gravity. The primary function of the separator is to maintain the purity of the serum or plasma by 1) preventing the serum or plasma from remixing with the blood cells, and 2) preventing the serum or plasma from becoming contaminated by the blood cells as they degrade.
A preferred separator is a thixotropic gel. This is a hydrophobic gel which is initially solid, but becomes liquefied during centrifugation so that it can migrate to form a layer between the serum or plasma and the blood cells (and other solids). A preferred thixotropic gel is a polyester based formulation, however any thixotropic gel can be used. Other nonlimiting examples are a mixture of silicon fluid and a hydrophobic powdered silica or a mixture of a hydrocarbon polymer and a powdered silica. Another preferred embodiment uses a thixotropic gel which is UV-curable in order to improve the strength of the barrier that is formed between the serum or plasma and the blood cells and other solids. Alternative types of separators include mechanical separators (e.g. elastomer barriers such as used in BD Barricor technology) and filter-based separators.
In the preferred embodiment shown in
An important element of the present invention is the cap design, which includes a reservoir large enough to contain the blood cells from the specimen along with any other solids or separator to be removed. The advantage of containing and capturing blood cells, other solids and any separator within the cap is that when the cap is removed, the blood cells and any other solids or separator are removed with the cap, leaving only serum or plasma in the specimen tube to be pipetted.
Another important element of the present invention is the technique of centrifuging the specimen container while oriented with the closed end of the cap further away from the axis of centrifugation than the closed end of the specimen tube. Centrifuging the specimen container with the closed end of the cap further way from the axis of centrifugation than the closed end of the specimen tube captures the blood cells, other solids and any separator in the reservoir in the cap. This enables the blood cells, other solids and any separator to be removed from the specimen when the cap is removed after centrifugation leaving just the serum or plasma in the specimen tube to be extracted for testing.
While particular embodiments of the invention have been described and illustrated, it is not intended that the invention be limited thereto. It is intended that the invention be as broad in scope as the art will allow and that the disclosure herein be interpreted likewise.
This embodiment shall also embody any configuration wherein the closed end of the cap can be unsealed and resealed such that a cannula can insert blood through the closed end of the cap.
In another preferred embodiment, the volume inside the specimen container is evacuated. This causes the blood specimen to be pulled into the specimen container by air pressure.
The figures show the specimen container and cap having a screw-type connection in order to connect the cap to the top end of the specimen container. A screw-type connection is the preferred embodiment as it provides the most secure seal for centrifugation. However, the cap may be attached to the specimen container by a variety of methods. A few examples are provided but the invention should not be limited to the examples and should include any method for securing the cap to the specimen container. A stopper-type connection may be used, but extra sealing pressure may be required to be applied during centrifugation. A gasket between the tube and the cap may be useful in such an embodiment to improve the seal.
The preferred embodiment described and illustrated show the specimen tube and cap as standalone components. In another embodiment, the cap may be physically tethered to the specimen container so that they are always connected. Once the blood specimen is centrifuged to separate the serum or plasma from the blood cells and other solids, the cap should be able to be opened such that a pipette is able to be inserted into the specimen tube to pipette the serum or plasma or such that the serum or plasma can be poured out into a separate container such as a different specimen tube.
An alternative embodiment is to integrate the cap into another device. For example, a blood collection device with a threaded opening could act as the cap for a specimen tube. This blood collection device could have a dual function where it puts blood into the specimen tube and also acts as the cap.
An alternative embodiment is to have a single device which functions as multiple caps. For example, a single plastic device with multiple threaded openings could act as the cap for multiple specimen tubes, with each threaded opening having its own reservoir. What is essential is that each threaded opening, which acts as a cap, contains a reservoir large enough to hold the blood cells and any other solids or separator.
An alternative embodiment is to have a single device which functions as multiple specimen tubes. For example, a multi-well plate could act as multiple specimen tubes, with each well in the plate capable of being secured by a cap which contains a reservoir.
The preferred embodiments described and illustrated in
The preferred embodiment described and illustrated describe the separation of serum or plasma from whole blood. This implies the possible use of chemical additives to the whole blood. For instance, to separate serum, a clot activator such as silica may be used. To separate plasma, an anticoagulant such as lithium heparin or potassium EDTA can be used. This invention is not limited to the use of any particular additive.
This application is a continuation of U.S. patent application Ser. No. 16/061,309, filed Jun. 11, 2018, now U.S. Pat. No. 10,870,110, which is a U.S. National Phase application, filed under U.S.C. § 371(c), of International Application No. PCT/US2016/066236, filed Dec. 12, 2016, which claims priority of U.S. Provisional Appl. No. 62/266,433, filed Dec. 11, 2015, both of which are incorporated by reference herein in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
1892884 | Grauman | Jan 1933 | A |
2110237 | Parsons | Mar 1938 | A |
2240101 | Smith | Apr 1941 | A |
2722257 | Lockhart | Nov 1955 | A |
2775350 | Jones | Dec 1956 | A |
2896502 | Nordin | Jul 1959 | A |
2912895 | Hamilton | Nov 1959 | A |
3081029 | Gauslaa | Mar 1963 | A |
3300051 | Mitchell | Jan 1967 | A |
3326400 | Hamelin et al. | Jun 1967 | A |
3419179 | Deuschle et al. | Dec 1968 | A |
3420107 | Rowett | Jan 1969 | A |
3434859 | Benjamin | Mar 1969 | A |
3478889 | Fessler | Nov 1969 | A |
3481712 | Bernstein et al. | Dec 1969 | A |
3508653 | Coleman | Apr 1970 | A |
3525254 | Milanes | Aug 1970 | A |
3539300 | Stone | Nov 1970 | A |
3611403 | Gilford et al. | Oct 1971 | A |
3615222 | Mead | Oct 1971 | A |
3626929 | Sanz et al. | Dec 1971 | A |
3654925 | Holderith | Apr 1972 | A |
3684455 | Vacirca | Aug 1972 | A |
3701434 | Moore | Oct 1972 | A |
3706305 | Berger | Dec 1972 | A |
3706306 | Berger | Dec 1972 | A |
3733179 | Guehler | May 1973 | A |
3750645 | Bennett | Aug 1973 | A |
3761408 | Lee | Sep 1973 | A |
3768979 | Mead | Oct 1973 | A |
3780935 | Lukacs | Dec 1973 | A |
3786985 | Blaivas | Jan 1974 | A |
3814248 | Lawhead | Jun 1974 | A |
3818188 | Hertel et al. | Jun 1974 | A |
3849072 | Ayres | Nov 1974 | A |
3852194 | Zine, Jr. | Dec 1974 | A |
3862042 | Ayres | Jan 1975 | A |
3879295 | Glover | Apr 1975 | A |
3920549 | Gigliello | Nov 1975 | A |
3926521 | Ginzel | Dec 1975 | A |
3928139 | Dorn | Dec 1975 | A |
3929646 | Adler | Dec 1975 | A |
3931010 | Ayres | Jan 1976 | A |
3938953 | Paschalis | Feb 1976 | A |
3939822 | Markowitz | Feb 1976 | A |
3942717 | Robison | Mar 1976 | A |
3958944 | Wong | May 1976 | A |
3972812 | Gresl, Jr. | Aug 1976 | A |
3985649 | Eddelman | Oct 1976 | A |
3999868 | Sanz | Dec 1976 | A |
4012325 | Columbus | Mar 1977 | A |
4046699 | Zine, Jr. | Sep 1977 | A |
4050451 | Columbus | Sep 1977 | A |
4052320 | Jakubowicz | Oct 1977 | A |
4055501 | Cornell | Oct 1977 | A |
D246800 | Wong | Dec 1977 | S |
4081356 | Zierdt | Mar 1978 | A |
4083788 | Ferrara | Apr 1978 | A |
4088582 | Murty | May 1978 | A |
4092113 | Hardy et al. | May 1978 | A |
4131512 | Dorn | Dec 1978 | A |
4131549 | Ferrara | Dec 1978 | A |
4132225 | Whattam | Jan 1979 | A |
4136036 | Columbus | Jan 1979 | A |
4147628 | Bennett | Apr 1979 | A |
4154690 | Bailies | May 1979 | A |
4164449 | Dorn | Aug 1979 | A |
4169060 | Columbus | Sep 1979 | A |
4180465 | Murty | Dec 1979 | A |
4227620 | Conway | Oct 1980 | A |
4235725 | Semersky | Nov 1980 | A |
4257886 | Kessler | Mar 1981 | A |
4294707 | Ikeda | Oct 1981 | A |
4295974 | Cornell | Oct 1981 | A |
4308232 | Crouther | Dec 1981 | A |
4358425 | Finney et al. | Nov 1982 | A |
4369117 | White | Jan 1983 | A |
4417981 | Nugent | Nov 1983 | A |
4425235 | Cornell | Jan 1984 | A |
4426290 | Ichikawa | Jan 1984 | A |
4443408 | Mintz | Apr 1984 | A |
4513522 | Selenke | Apr 1985 | A |
4591486 | Eberle | May 1986 | A |
4671939 | Mintz | Jun 1987 | A |
4678559 | Szabados | Jul 1987 | A |
4735904 | Starr | Apr 1988 | A |
4755356 | Robbins | Jul 1988 | A |
4762798 | Deutsch | Aug 1988 | A |
4775626 | Armenta | Oct 1988 | A |
4805772 | Shaw et al. | Feb 1989 | A |
4811866 | Golias | Mar 1989 | A |
4832678 | Sheeran | May 1989 | A |
4957707 | Hofelich | Sep 1990 | A |
5019243 | McEwen | May 1991 | A |
5030341 | McEwen | Jul 1991 | A |
5090420 | Nielsen | Feb 1992 | A |
5104533 | Szabados | Apr 1992 | A |
5151184 | Ferkany | Sep 1992 | A |
5236604 | Fiehler | Aug 1993 | A |
5275731 | Jahn | Jan 1994 | A |
5290703 | Hsu | Mar 1994 | A |
5316146 | Graff | May 1994 | A |
5352410 | Hansen et al. | Oct 1994 | A |
5501841 | Lee et al. | May 1996 | A |
5556544 | Didier | Sep 1996 | A |
5614236 | Klang | Mar 1997 | A |
5632905 | Haynes | May 1997 | A |
5665309 | Champseix et al. | Sep 1997 | A |
5683659 | Hovatter | Nov 1997 | A |
5830154 | Goldstein | Nov 1998 | A |
5882318 | Boyde | Mar 1999 | A |
5882943 | Aldeen | Mar 1999 | A |
5975313 | Sarstedt | Nov 1999 | A |
6043878 | Gratzl et al. | Mar 2000 | A |
6132353 | Winkelman et al. | Oct 2000 | A |
6171261 | Niermann | Jan 2001 | B1 |
6221655 | Fung | Apr 2001 | B1 |
6234948 | Yavilevich | May 2001 | B1 |
6270728 | Wijnschenk et al. | Aug 2001 | B1 |
6296763 | Hicks | Oct 2001 | B1 |
6344331 | Ball | Feb 2002 | B1 |
6471069 | Lin | Oct 2002 | B2 |
6497325 | DiCesare et al. | Dec 2002 | B1 |
6730071 | Dassa | May 2004 | B1 |
6793885 | Yokoi | Sep 2004 | B1 |
7176034 | Efthimiadis | Feb 2007 | B2 |
7638342 | Samsoondar | Dec 2009 | B2 |
7736593 | Dastane | Jun 2010 | B2 |
8343426 | Song | Jan 2013 | B2 |
8550273 | Levin | Oct 2013 | B2 |
8632740 | Dastane et al. | Jan 2014 | B2 |
8852505 | Dupoteau et al. | Oct 2014 | B2 |
9251393 | Pollack | Feb 2016 | B2 |
9279760 | Imazu et al. | Mar 2016 | B2 |
9488563 | Halverson | Nov 2016 | B2 |
9604219 | Mortillaro et al. | Mar 2017 | B2 |
10870110 | Olson | Dec 2020 | B2 |
20010025818 | Warner | Oct 2001 | A1 |
20020040872 | Bogoev | Apr 2002 | A1 |
20020066712 | Brockwell | Jun 2002 | A1 |
20020155619 | Kurihara et al. | Oct 2002 | A1 |
20030091701 | Yahav | May 2003 | A1 |
20030209091 | Fattinger | Nov 2003 | A1 |
20040005246 | Efthimiadis | Jan 2004 | A1 |
20040059255 | Manoussakis | Mar 2004 | A1 |
20040129631 | Anraku | Jul 2004 | A1 |
20050014273 | Dahm et al. | Jan 2005 | A1 |
20050059163 | Dastane et al. | Mar 2005 | A1 |
20050123444 | Tomasso et al. | Jun 2005 | A1 |
20050132775 | Laugharn, Jr. | Jun 2005 | A1 |
20060009713 | Flaherty | Jan 2006 | A1 |
20060142669 | Morimoto | Jun 2006 | A1 |
20070020629 | Ross et al. | Jan 2007 | A1 |
20070073187 | Thomson et al. | Mar 2007 | A1 |
20070083131 | Escutia et al. | Apr 2007 | A1 |
20070110627 | Nagai et al. | May 2007 | A1 |
20070231834 | Hale | Oct 2007 | A1 |
20080003148 | Dause | Jan 2008 | A1 |
20080096282 | Samsoondar | Apr 2008 | A1 |
20080185349 | Willliams | Aug 2008 | A1 |
20080213377 | Bhatia et al. | Sep 2008 | A1 |
20080237115 | Shintani | Oct 2008 | A1 |
20080286150 | Pankow | Nov 2008 | A1 |
20080313877 | Campbell | Dec 2008 | A1 |
20090257922 | Baker | Oct 2009 | A1 |
20100062415 | Schwoebel | Mar 2010 | A1 |
20100111773 | Pantelidis | May 2010 | A1 |
20100114056 | Nagai | May 2010 | A1 |
20100261988 | Tamir | Oct 2010 | A1 |
20100288060 | Ronsick | Nov 2010 | A1 |
20100294050 | Massaro | Nov 2010 | A1 |
20100303688 | Andersen | Dec 2010 | A1 |
20110263408 | Suto et al. | Oct 2011 | A1 |
20120048002 | Mallet | Mar 2012 | A1 |
20120048827 | Levin | Mar 2012 | A1 |
20120053041 | Ihm et al. | Mar 2012 | A1 |
20120058027 | Song | Mar 2012 | A1 |
20120258531 | Seubert | Oct 2012 | A1 |
20130045477 | Harder | Feb 2013 | A1 |
20130045852 | Chapman et al. | Feb 2013 | A1 |
20130125628 | Kitagawa et al. | May 2013 | A1 |
20130167768 | Smith | Jul 2013 | A1 |
20130209985 | Hoke | Aug 2013 | A1 |
20130224851 | Ljungmann et al. | Aug 2013 | A1 |
20130280130 | Sarwar et al. | Oct 2013 | A1 |
20130323711 | Singh | Dec 2013 | A1 |
20140065018 | Imazu et al. | Mar 2014 | A1 |
20140073990 | Holmes et al. | Mar 2014 | A1 |
20140096598 | Halverson | Apr 2014 | A1 |
20140105796 | Nagy | Apr 2014 | A1 |
20140113278 | Thomas et al. | Apr 2014 | A1 |
20140241957 | Serhan et al. | Aug 2014 | A1 |
20140255254 | Yamaguchi et al. | Sep 2014 | A1 |
20140273242 | Ochranek et al. | Sep 2014 | A1 |
20140296089 | Holmes et al. | Oct 2014 | A1 |
20140356254 | Lee | Dec 2014 | A1 |
20140374480 | Pollack | Dec 2014 | A1 |
20150018715 | Walterspiel | Jan 2015 | A1 |
20150056716 | Oyler | Feb 2015 | A1 |
20150072346 | Gellibolian | Mar 2015 | A1 |
20150111299 | Watabe et al. | Apr 2015 | A1 |
20150151294 | Cho | Jun 2015 | A1 |
20150289856 | Saqi | Oct 2015 | A1 |
20150316532 | Makino et al. | Nov 2015 | A1 |
20160097049 | Qian | Apr 2016 | A1 |
20180028102 | George et al. | Feb 2018 | A1 |
20180259251 | Poorte et al. | Sep 2018 | A1 |
20180326413 | Walkowiak | Nov 2018 | A1 |
20180353952 | Olson | Dec 2018 | A1 |
Number | Date | Country |
---|---|---|
2058917 | Jul 1993 | CA |
1501080 | Jun 2004 | CN |
1690714 | Nov 2005 | CN |
1826530 | Aug 2006 | CN |
1856366 | Nov 2006 | CN |
1863495 | Nov 2006 | CN |
101311700 | Nov 2008 | CN |
101312689 | Nov 2008 | CN |
101454665 | Jun 2009 | CN |
101678931 | Mar 2010 | CN |
201454557 | May 2010 | CN |
102033007 | Apr 2011 | CN |
102209896 | Oct 2011 | CN |
102764133 | Nov 2012 | CN |
102933949 | Feb 2013 | CN |
103123317 | May 2013 | CN |
103308376 | Sep 2013 | CN |
103354765 | Oct 2013 | CN |
103393427 | Nov 2013 | CN |
103608658 | Feb 2014 | CN |
103674672 | Mar 2014 | CN |
104034672 | Sep 2014 | CN |
104107054 | Oct 2014 | CN |
203965173 | Nov 2014 | CN |
104768516 | Jul 2015 | CN |
105600468 | May 2016 | CN |
494845 | Jul 1992 | EP |
1005910 | Jun 2000 | EP |
1161923 | Dec 2001 | EP |
1542020 | Jun 2005 | EP |
1884188 | Feb 2008 | EP |
2582013 | Nov 1986 | FR |
S48-041632 | Dec 1973 | JP |
3-181852 | Mar 1991 | JP |
H03181852 | Aug 1991 | JP |
H05-26883 | Feb 1993 | JP |
H08-21839 | Jan 1996 | JP |
H09166591 | Jun 1997 | JP |
H10-033507 | Feb 1998 | JP |
10-243940 | Sep 1998 | JP |
10277019 | Oct 1998 | JP |
11318870 | Nov 1999 | JP |
2000-084389 | Mar 2000 | JP |
2001-264344 | Sep 2001 | JP |
2007-503580 | Feb 2007 | JP |
2007271388 | Oct 2007 | JP |
2008-506128 | Feb 2008 | JP |
2008-099991 | May 2008 | JP |
2008-191070 | Aug 2008 | JP |
2009-507237 | Feb 2009 | JP |
2009089759 | Apr 2009 | JP |
2012-527613 | Nov 2012 | JP |
2014-048112 | Mar 2014 | JP |
2014-173904 | Sep 2014 | JP |
2015-509202 | Mar 2015 | JP |
WO-8505048 | Nov 1985 | WO |
WO-9839650 | Sep 1998 | WO |
0170403 | Sep 2001 | WO |
WO-2005014173 | Feb 2005 | WO |
WO 2008027319 | Mar 2008 | WO |
2008119947 | Oct 2008 | WO |
WO 2013003308 | Jan 2013 | WO |
WO 2014050021 | Sep 2013 | WO |
WO 2014050021 | Apr 2014 | WO |
WO 2017100798 | Jun 2017 | WO |
WO 2018090023 | May 2018 | WO |
WO 2018090027 | May 2018 | WO |
WO 2018090030 | May 2018 | WO |
Entry |
---|
PCT Written Opinion and Search Report for International Application No. PCT/US2016/066236, dated Mar. 3, 2017. |
Office Action and English Translation for CN Application No. 201680081591.7, dated Sep. 1, 2020. |
European Search Report for EP Application No. 20209543 dated Jun. 9, 2021, 1-9. |
International Search Report dated Feb. 2, 2018 in corresponding PCT Application No. PCT/US2017/061596. |
International Search Report dated Jan. 29, 2018 in corresponding PCT Application No. PCT/US2017/061592. |
International Search Report for PCT/US2017/061585 dated Jan. 17, 2018. |
Office Action for Chinese Application No. CN20178083377, dated Mar. 4, 2022, 21 pages. |
Office Action for Japanese Application No. JP2019525902, dated Jan. 20, 2022, 5 pages. |
Office Action for Chinese Application No. 202110946196, dated Jun. 22, 2022, 29 pages. |
Office Action for Chinese Application No. 201780083377, dated Sep. 1, 2022, 18 pages. |
Office Action for Chinese Application No. CN202110946196.3 dated Mar. 7, 2023, 14 pages. |
Number | Date | Country | |
---|---|---|---|
20210039088 A1 | Feb 2021 | US |
Number | Date | Country | |
---|---|---|---|
62266433 | Dec 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16061309 | US | |
Child | 17082759 | US |